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Part of this work was published in abstract form as part of the conference proceedings of Experimental Biology 2019 (Soave et al., 2019a).SUMMARYCamelid single-domain antibody fragments (nanobodies) offer the specificity of an antibody in a single 15-
kDa immunoglobulin domain. Their small size allows for easy genetic manipulation of the nanobody
sequence to incorporate protein tags, facilitating their use as biochemical probes. The nanobody VUN400,
which recognizes the second extracellular loop of the human CXCR4 chemokine receptor, was used as a
probe to monitor specific CXCR4 conformations. VUN400 was fused via its C terminus to the 11-amino-
acid HiBiT tag (VUN400-HiBiT) which complements LgBiT protein, forming a full-length functional NanoLuc
luciferase. Here, complemented luminescence was used to detect VUN400-HiBiT binding to CXCR4 recep-
tors expressed in living HEK293 cells. VUN400-HiBiT binding to CXCR4 could be prevented by orthosteric
and allosteric ligands, allowing VUN400-HiBiT to be used as a probe to detect allosteric interactions with
CXCR4. These data demonstrate that the high specificity offered by extracellular targeted nanobodies can
be utilized to probe receptor pharmacology.INTRODUCTION
The C-X-C chemokine receptor 4 (CXCR4) is a family A G pro-
tein-coupled receptor (GPCR) that plays an important role in
the immune response and in the progression of many diseases,
including cancer and HIV infection (Kucia et al., 2004; Scholten
et al., 2012). As a GPCR, CXCR4 consists of seven transmem-
brane helices, an extracellular N terminus, and an intracellular
C terminus. Of the chemokine receptor family, CXCR4 is unusual
in that it exclusively binds one chemokine ligand, CXCL12
(formerly termed stromal cell-derived factor 1a). CXCL12 binds
to CXCR4 in a two-step process: first interacting with residues
in the N terminus of the receptor (chemokine recognition site
1), before CXCL12 engages both the extracellular loops and
binding pocket within the transmembrane helices (chemokine
recognition site 2 [CR2]; Kofuku et al., 2009). Mutation studies
have shown that the N terminus of the receptor contributes to
chemokine binding, whereas the binding pocket within the trans-
membrane helices is responsible for receptor activation and
binding affinity (Scholten et al., 2012). The structure of CXCR4
has since been solved in the presence of the small-molecule
antagonist IT1t, the cyclic peptide antagonist CVX15 (Wu et al.,
2010), and the chemokine antagonist vMIP-II (Qin et al., 2015).Cell Chemical Biology 27, 1–12,
This is an open access article undFurthermore, CXCR4-targeting small molecules bind to a site
that partially or wholly overlaps with CR2 (Arimont et al., 2017).
Although CXCR4 only binds one type of chemokine, CXCL12,
these studies have shown that CXCR4 is able to adopt many
different conformations in order to accommodate and bind
these different classes of ligands.
Due to the critical role played by CXCR4 in HIV infection and
tumor progression, there has been considerable interest in
developing specific CXCR4 antagonists, a number of which
are in the clinical development pipeline (Kuhne et al., 2013;
www.clinicaltrials.gov). Despite this, only the small-molecule
CXCR4-negative allosteric modulator AMD3100 (Plerixafor, Mo-
zobil) has received Food and Drug Administration approval for
the treatment of lymphoma and multiple myeloma (Keating,
2011) and the treatment of Hodgkin lymphoma in Europe (Doug-
las et al., 2018). AMD3100 has also been demonstrated to be a
weak allosteric agonist of the atypical chemokine receptor 3
(ACKR3; previously CXCR7), inducing b-arrestin recruitment
in vitro (Kalatskaya et al., 2009). This, in addition to its short
serum half-life in vivo (Hendrix et al., 2000), has necessitated
the development of more selective, long-lasting antagonists.
The improved selectivity and extended half-lives of antibodies
compared with small molecules has meant there has beenAugust 20, 2020 ª 2020 The Authors. Published by Elsevier Ltd. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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CXCR4 therapeutically (Hutchings et al., 2017; Bobkov et al.,
2019). This has included the recent development of a panel of
single-domain antibody fragments, called nanobodies, which
are able to bind CXCR4 (Jahnichen et al., 2010; de Wit et al.,
2017; Bobkov et al., 2018; Van Hout et al., 2018).
Nanobodies are small proteins (circa 12–15 kDa), derived from
the single variable fragments (VHH) of heavy-chain-only anti-
bodies found in members of the Camelidae family. Nanobodies
are known to be excellent conformational sensors due to their
small size and three-dimensional structure (De Genst et al.,
2006). Furthermore, their elongated complementary determining
region 3 (CDR3) enables nanobodies to engage hidden cavities
and conformational epitopes (DeGenst et al., 2006). Nanobodies
have been extensively used within the GPCR field to stabilize
specific receptor conformations for crystallization (Rasmussen
et al., 2011; Ring et al., 2013; Kruse et al., 2013; Huang et al.,
2015; Che et al., 2018) and to elucidate new conformational
states (Staus et al., 2016). This has also led to the development
of these nanobodies as biosensors to investigate GPCR
signaling (Irannejad et al., 2013; Staus et al., 2014, 2016; Stoeber
et al., 2018). The nanobodies used in these studies generally
target intracellular regions of the GPCR, often binding in the
same pocket as G proteins to act as G protein mimetics (Ras-
mussen et al., 2011; Staus et al., 2014; Stoeber et al., 2018).
Nanobodies that bind to the extracellular domains of GPCRs
are able tomodulate receptor activity and organization (De Groof
et al., 2019a). Several studies have investigated the therapeutic
potential of extracellular nanobodies that target chemokine
GPCRs, including CXCR2 (Bradley et al., 2015), CXCR4 (Jahni-
chen et al., 2010; de Wit et al., 2017; Bobkov et al., 2018; Van
Hout et al., 2018), ACKR3 (Maussang et al., 2013), and US28
(De Groof et al., 2019b). Given their relatively large N terminus
compared with the other class A GPCRs and the fact that their
endogenous ligands are peptides, chemokine GPCRs are ideal
candidates to target with extracellular nanobodies. Most
recently, several nanobodies binding to the N terminus and sec-
ond extracellular loop (ECL2) of CXCR4were generated (Bobkov
et al., 2018; Van Hout et al., 2018). For example, VUN400 was
one of these nanobodies that acted as an antagonist and
inhibited CXCL12-induced signaling by CXCR4, as well as inter-
nalization. Interestingly, VUN400 also showed a decreased po-
tency of inhibiting CXCR4-mediated HIV-1 entry compared
with its ability to inhibit CXCL12-induced signaling, suggesting
a conformational sensitivity of the nanobody (Van Hout
et al., 2018).
The recently developed NanoLuc binary technology (NanoBiT)
splits the bright NanoLuc luciferase into two segments at the
C-terminal region, the 18-kDa fragment (termed LgBiT), and
the 1.3-kDa small complementation tag (termed SmBiT; Dixon
et al., 2016). These fragments have low intrinsic affinity and com-
plement to form the full luminescent NanoLuc protein but with a
reduced luminescence compared with the full-length NanoLuc
(Dixon et al., 2016). Other small complementary peptides with
a range of affinities for LgBiT have been identified, including an
11-amino-acid sequence with very high affinity, termed HiBiT.
The complemented HiBiT-LgBiT protein showed a luminescence
output similar to that of the full-length NanoLuc, making it an
ideal system to study proteins expressed at endogenous levels2 Cell Chemical Biology 27, 1–12, August 20, 2020(Schwinn et al., 2018). NanoBiT has been used to monitor pro-
tein-protein interactions, including GPCR oligomerization (Botta
et al., 2019), and the recruitment of G proteins and b-arrestin to
GPCRs (Hisano et al., 2019; Laschet et al., 2018; Storme et al.,
2018), with the rapid complementation and maturation rate of
the split NanoLuc luciferase enabling kinetic measurements.
These studies made use of GPCRs with NanoBiT fused to their
C-terminal domains. In addition, we have recently demonstrated
the use of N-terminally-fused NanoBiT to monitor adenosine A1
receptor internalization in vitro (Soave et al., 2019b), showing it
was possible to use NanoBiT to measure the membrane expres-
sion of GPCRs in living cells.
The HiBiT-LgBiT system has also recently been used to
monitor conformational changes in CXCR4 following CRISPR/
Cas9-mediated homology-directed repair to insert HiBiT onto
the N terminus of CXCR4 within the endogenous genome (White
et al., 2020). This study showed that AMD3100 induced amarked
increase in luminescence following complementation of the
HiBiT attached to the N terminus of endogenous CXCR4with pu-
rified LgBiT (White et al., 2020). This was proposed to be a
consequence of changes in affinity of HiBiT for LgBiT as a result
of extracellular conformational changes in CXCR4 induced by
AMD3100, reducing the steric hindrance imparted by the recep-
tor to which HiBiT was attached (White et al., 2020).
Here, we have used the NanoBiT technology in combination
with the ECL2-directed nanobody VUN400 to directly monitor
changes in the conformation of CXCR4 induced by AMD3100,
CXCL12, and IT1t in living cells.
RESULTS
Characterization of LgBiT-CXCR4 with NanoBiT
As part of the necessary tool development, we initially used the
NanoBiT technology to characterize the binding of VUN400 to
CXCR4. To establish this technique, we first modified the N ter-
minus of the human CXCR4 receptor through the fusion of the
large NanoLuc subunit (LgBiT [Dixon et al., 2016]). This receptor
(LgBiT-CXCR4) was successfully expressed at the plasma
membrane in HEK293 cells and could be detected following
the addition of 10 nM exogenous purified HiBiT by monitoring
luminescence (Figures 1A–1C). HiBiT was added in the form of
a purified HiBiT-HaloTag fusion protein, circa 34 kDa in size,
which was too large to cross the plasma membrane. There
was significantly increased luminescence in HEK293 cells stably
expressing LgBiT-CXCR4 compared with untransfected
HEK293 cells (Figure 1B). The continuous monitoring of comple-
mented luminescence allowed for the kinetic rate constants for
HiBiT at the LgBiT-CXCR4 to be determined (kon 6.03 3 10
5 ±
0.97 3 105 M1 min1; koff 0.22 ± 0.03 min
1; pKD 6.43 ± 0.13;
n = 3; Figure 1D). However, it was noticeable that there was a
small drop in luminescence signal after about 10 min with higher
concentrations of purified HiBiT (Figure 1D).
The addition of purified HiBiT to LgBiT-CXCR4 resulted in the
fully complemented NanoLuc-CXCR4 (Figure 2A), thus allowing
NanoBRET to be performed to monitor ligand binding at the
plasma membrane. Specific binding of fluorescently labeled
CXCL12 (CXCL12-AF647; Van Hout et al., 2018) could be
detected at the LgBiT-CXCR4 using the previously
described NanoBRET ligand binding (Stoddart et al., 2015)
Figure 1. Luminescence to Monitor Plasma Membrane Expression of LgBiT-CXCR4
(A) Schematic of NanoBiT complementation to detect receptor expression.
(B and C) PHERAstar-detected luminescence (B) and bioluminescent imaging (C) of HEK293 cells or HEK293 cells stably expressing LgBiT-CXCR4 following
treatment with 20 nM HiBiT-HaloTag and furimazine. Scale bar, 20 mm.
(D) Complemented luminescence of LgBiT-CXCR4 over time following addition of multiple HiBiT concentrations.
These single experiments are representative of four (B) five (C), or three (D) separate experiments. Data are mean + SEM. from triplicate determinations in a single
experiment.
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the LgBiT-CXCR4 receptor was expressed at the plasma mem-
brane, the LgBiT tag did not interfere with ligand binding, and the
LgBiT-CXCR4 receptor was able to bind the fluorescent orthos-
teric agonist with high affinity.
Generation of HiBiT-Tagged VUN400
Next, a nanobody-HiBiT fusion construct was generated. We
used the previously described nanobody, VUN400, as this is
known to bind to key residues in ECL2 of the CXCR4 receptor
(Bobkov et al., 2018; Van Hout et al., 2018). VUN400-HiBiT
was expected to bind in close proximity to the N-terminal LgBiT
on the LgBiT-CXCR4 receptor, increasing the likelihood of HiBiT-
LgBiT complementation upon nanobody binding to the LgBiT-
CXCR4. The plasmid DNA encoding the VUN400 nanobody
wasmodified at the 30 end by the incorporation of the oligonucle-
otide HiBiT tag (amino acid sequence: VSGWRLFKKIS) in be-
tween the C-terminal Myc and His tags (Figure 3A), creating a
VUN400-HiBiT fusion construct.
The ability of the VUN400-HiBiT to bind to the LgBiT-CXCR4
receptor was investigated thereafter (Figure 3B). Increasing con-
centrations of VUN400-HiBiT resulted in a saturable increase in
luminescence, with an affinity of circa 60 nM, corresponding to
a pKD value of 7.25 ± 0.08 (n = 4) (Figure 3C). Specific binding
of VUN400-HiBiT at the LgBiT-CXCR4 receptor was visualized
using bioluminescence microscopy (Figure 3C, inset), showing
clear plasma membrane luminescence. To confirm that the
observed affinity was predominantly a result of nanobody-recep-
tor binding, we treated HEK LgBiT-CXCR4 cells with increasingconcentrations of purified HiBiT (Figure 3D). Over the concentra-
tion range of purified HiBiT employed, binding was effectively
linear, indicative of low affinity (Figure 3D). The affinity of this
interaction was significantly lower than that measured with
VUN400-HiBiT, suggesting that NanoBiT complementation
was not driving the VUN400-HiBiT affinity measured above.
VUN400-HiBiT binding to LgBiT-CXCR4 could be prevented by
pre-treatment with a fixed concentration of CXCL12 as well as
the small-molecule negative allosteric modulators AMD3100
and IT1t (Figure 3E).
Continuous monitoring of complemented luminescence made
it possible to perform association kinetic experiments in order to
assess the binding kinetics of VUN400-HiBiT at the LgBiT-
CXCR4. As expected, complemented luminescence increased
over time and with increasing concentrations of VUN400-HiBiT
(Figure 3F). Global analysis of these data produced the kinetic
rate constants kon 1.98 3 10
5 ± 0.15 3 105 M1 min1 and koff
0.032 ± 0.003min1 (n = 4), and the equilibrium dissociation con-
stant determined from these rate constants (pKD 6.79 ± 0.16)
was in good agreement with that determined from equilibrium
saturation binding experiments (Figure 3C; p > 0.05, unpaired t
test). There was, however, a small drop in luminescence after
40min at the highest concentrations of VUN400-HiBiT employed
(Figure 3F), likely due to substrate depletion.
VUN400-HiBiT to Detect Endogenous CXCR4 Receptors
The high-affinity binding between VUN400-HiBiT and CXCR4
provided the opportunity to monitor ligand binding at CXCR4
receptors expressed under endogenous expression. TheCell Chemical Biology 27, 1–12, August 20, 2020 3
Figure 2. Complemented NanoBiT to
Perform NanoBRET Ligand Binding
(A) Schematic of NanoBiT complementation to
perform NanoBRET ligand binding.
(B) NanoBRET saturation binding of CXCL12-
AF647 in the absence (black circles) or presence
(red circles) of 10 mM AMD3100 at complemented
LgBiT-CXCR4. Data are mean ± SEM from tripli-
cate determinations in a single experiment. These
single experiments are representative of four
separate experiments.
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high levels of CXCR4 endogenously. Jurkat cells were treated
with 100 nM VUN400-HiBiT in combination with competing
ligands for 2 h. Jurkat cells were then washed to remove any
unbound VUN400-HiBiT, and full-length NanoLuciferase was
complemented with the addition of 10 nM exogenous LgBiT.
Binding of VUN400-HiBiT to endogenous, untagged CXCR4
could be detected using this setup (Figure 4A). In addition,
VUN400-HiBiT could be displaced by the addition of CXCL12,
AMD3100, and IT1t (Figure 4A; p < 0.05), demonstrating the
sensitivity of complemented luminescence as an experimental
readout for monitoring nanobody-receptor binding. Two high
ligand concentrations were chosen to confirm that maximal
VUN400-HiBiT displacement was reached. VUN400-HiBiT was
able to probe for the differences in receptor expression between
the overexpressing LgBiT-CXCR4 cell line and the Jurkat cell
line. Here, the Jurkat cell line was found to express the CXCR4
receptor at lower levels than that of the LgBiT-CXCR4 cell
line (15.2% ± 5.4% expression compared with LgBiT-CXCR4;
n = 4; Figure 4B).
VUN400-HiBiT as a Probe to Detect Binding of CXCL12
or Small-Molecule Antagonists
The ability of ligands to interfere with VUN400-HiBiT binding to
the LgBiT-CXCR4 receptor was investigated further. Whole cells
were treated with 20 nM VUN400-HiBiT for 30 min and then
challenged with a 2-h incubation with CXCR4 ligands. The or-
thosteric agonist CXCL12 appeared to reduce VUN400-HiBiT
binding to LgBiT-CXCR4 (pIC50 8.82 ± 0.12; n = 5; Figure 5A
and Table 1a). AMD3100 and IT1t were also able to reduce the
luminescence resulting from VUN400-HiBiT binding in a concen-
tration-dependent manner (Figure 5A and Table 1a). This is likely
to be due to a dissociation of VUN400-HiBiT from the LgBiT-
CXCR4. Alternatively, the reduced signal could be a conse-
quence of a conformational change in CXCR4 that altered the
orientation of VUN400-HiBiT (binding to ECL2) with respect to4 Cell Chemical Biology 27, 1–12, August 20, 2020LgBiT on the N terminus of LgBiT-
CXCR4, which would prevent effective
complementation of the full-length
NanoLuciferase.
To determine whether the reduction in
bioluminescence upon AMD3100 or IT1t
treatment was due to altered biolumines-
cence complementation (e.g., a change in
orientation rather than displacement of
VUN400-HiBiT from the receptor), weinvestigated the binding of the VUN400-HiBiT to CXCR4 with
an N-terminal SNAP tag. As a 19-kDa protein, the SNAP tag is
similar in size to the full-length NanoLuc, thus acting as a steric
N-terminal control for HiBiT-LgBiT complementation. Addition-
ally, the SNAP tag was not luminescent. Therefore, following
several washes to remove unbound VUN400-HiBiT, exogenous
LgBiT (20 nM) was added at the end of the experiment to com-
plement VUN400-HiBiT bound to SNAP-CXCR4. VUN400-HiBiT
binding to the SNAP-CXCR4 receptor was observed (Figure S1).
However, bindingwas linear over the concentration of 1–500 nM,
indicative of lower affinity binding. The expression level (as
determined by the overall luminescence achieved) also ap-
peared to be much lower than that obtained with LgBiT-
CXCR4 (Figures S1 and 2). Nevertheless, AMD3100 was still
able to reduce the bioluminescence signals. Because comple-
mentation was achieved with LgBiT in solution, it was unlikely
that the reduced signals by AMD3100 were caused by changes
in HiBiT-LgBiT proximity. Therefore, these data suggest that
AMD3100 causes a reduction in signals by reducing the binding
of VUN400-HiBiT to CXCR4.
The binding of VUN400-HiBiT to SNAP-CXCR4 was inhibited
by CXCL12, AMD3100, and IT1t in a concentration-dependent
manner (Figure 5B and Table 1a). The resulting IC50 values of
AMD3100 and IT1t determined at the SNAP-CXCR4 were not
significantly different from those measured at the LgBiT-
CXCR4 (Table 1a, p > 0.05, unpaired t test), suggesting that
NanoBiT complementation between the VUN400-HiBiT and
LgBiT-CXCR4 had no effect on the ability of these antagonist li-
gands to prevent binding of the nanobody to CXCR4. Interest-
ingly, CXCL12 had a lower pIC50 value in the SNAP-CXCR4
cell line than in the LgBiT-CXCR4 cell line (p < 0.05, unpaired
t test).
Next, the effects of simultaneous addition of VUN400-HiBiT
and ligands were investigated. Whole cells were treated with
20 nM VUN400-HiBiT, which was added to the plate simulta-
neously with increasing concentrations of the endogenous
Figure 3. VUN400-HiBiT Binding to LgBiT-CXCR4
(A) Schematic of VUN400-HiBiT structure, with HiBiT amino acid tag positioned between C-proximal Myc and His tags.
(B) Schematic of VUN400-HiBiT binding LgBiT-CXCR4.
(C) Saturation binding of VUN400-HiBiT at the LgBiT-CXCR4. Inset: bioluminescent image of 20 nM VUN400-HiBiT binding LgBiT-CXCR4 following treatment
with furimazine.
(D) Saturation binding of purified HiBiT at the LgBiT-CXCR4.
(E) Saturation binding of VUN400-HiBiT at LgBiT-CXCR4 in the absence (black circles) or presence of 100 nM CXCL12 (open circles), 10 mM AMD3100 (red
circles), or 10 mM IT1t (blue circles). Data are expressed as a percentage of luminescence obtained with 250 nM VUN400-HiBiT alone.
(F) Association binding kinetics of VUN400-HiBiT at the LgBiT-CXCR4.
Data are mean ± SEM from triplicate or mean from duplicate (+10 mM AMD3100 in E) determinations in a single experiment. These single experiments are
representative of four separate experiments.
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AMD3100. Figure 5C shows a clear decrease in luminescence at
LgBiT-CXCR4 in the presence of high concentrations of
competing ligands (Table 1b). Similar results were obtained at
the SNAP-CXCR4 receptor (Figure 5D and Table 1b). Again,CXCL12 had a lower pIC50 value in the SNAP-CXCR4 cell line
than in the LgBiT-CXCR4 cell line (p < 0.05, unpaired t test).
Taken together, these data show that the binding of CXCL12,
AMD3100, and IT1t to N-terminally tagged CXCR4 receptors
can inhibit VUN400-HiBiT binding to ECL2 of the receptor,Cell Chemical Biology 27, 1–12, August 20, 2020 5
Figure 4. ‘VUN400-HiBit Binding in Immortalized T cells
(A) Complemented luminescence of Jurkat cells treated with 100 nM VUN400-
HiBiT in the absence or presence of CXCL12, AMD3100, or IT1t, following the
addition of 20 nM purified LgBiT. Also shown is the background luminescence
due to the addition of HEPES-buffered saline solution + 0.2% bovine serum
albumin in place of VUN400-HiBiT. Data are mean ± SEM from triplicate de-
terminations in a single experiment. This single experiment is representative of
six separate experiments. *p < 0.05, comparing ligand treatment with 100 nM
VUN400-HiBiT treatment alone, one-way ANOVA with Dunnett’s post hoc test
for multiple comparisons in this single experiment. Analysis of the complete
mean data obtained in all six repeat experiments were subjected to two-way
ANOVA (experiments and treatments between the two variables) and yielded
significant inhibitions (p < 0.05) by all ligand concentrations apart from 100 nM
CXCL12.
(B) VUN400-HiBiT to compare CXCR4 expression levels. Luminescence signal
from LgBiT-CXCR4 or Jurkat cells treated with 100 nM VUN400-HiBiT in the
absence and presence of 10 mM AMD3100. Complemented luminescence in
Jurkat cells was achieved with the addition of 20 nM purified LgBiT. Data are
mean ± SEM from triplicate determinations in a single experiment. This single
experiment is representative of four separate experiments.
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tional change may also change the orientation of the HiBiT on
VUN400-HiBiT bound to ECL2 with respect to LgBiT on the
N-terminal LgBiT-CXCR4 (effectively preventing complementa-
tion), allowing more sensitive detection of agonist-induced
conformational changes with the NanoLuciferase complementa-
tion approach than with traditional ligand binding approaches
(Figure 5).
Conformational Selectivity of VUN400-HiBiT
The VUN400 nanobody was originally selected using phage
display, utilizing CXCR4-expressing lipoparticles containing
high concentrations of CXCR4 in native conditions, and thus in
a myriad of specific conformations. Therefore, there was the po-
tential that VUN400 recognized a specific CXCR4 conformation
that could be modulated by ligand treatment. With this in mind,
we repeated the VUN400-HiBiT displacement experiments at
the LgBiT-CXCR4, incubating with CXCL12, AMD3100, or IT1t
prior to the addition of VUN400-HiBiT. The binding of VUN400-
HiBiT to LgBiT-CXCR4 was inhibited by all ligands with a higher
potency than when ligands and nanobody were added simulta-
neously (Figure 5E and Table 1c). This effect was particularly
marked with AMD3100, whereby the potency was an order of
magnitude higher when cells were pre-treated with AMD3100
for 2 h prior to addition of VUN400-HiBiT (Figure 5E and Table
1c). These data suggest that AMD3100 (and to a lesser extent
IT1t) can induce a conformation that has higher affinity for the
small molecule than when the nanobody is added at the same
time. This is suggestive of a negative allosteric interaction
between the binding sites for AMD3100 and VUN400-HiBiT,
but could also be due to the ECL2 bound nanobody sterically
interfering with access of the small-molecule inhibitor to its
transmembrane binding site. A similar observation was made
for AMD3100 with the SNAP-CXCR4 receptor (Figure 5E and
Table 1c).
Interestingly, in the case of CXCL12 binding to SNAP-CXCR4,
the inhibition curve appeared to be much less potent than in the
equivalent LgBiT-CXCR4 experiments and the plateau above
zero indicative of the presence of multiple components of
VUN400-HiBiT binding, one of whichwas insensitive to displace-
ment by low concentrations of CXCL12 (Figure 5F). This was not
a result of the N-terminal SNAP tag interfering with the binding of
CXCL12 to SNAP-CXCR4 (Figure S2). Time-resolved fluores-
cence energy transfer (TR-FRET) ligand binding confirmed an
affinity of CXCL12-AF647 (pKD 7.99 ± 0.10; n = 5, Figure S2)
that was in agreement with that measured at the LgBiT-CXCR4
with NanoBRET.
To determine the temporal characteristics of any conforma-
tional changes induced by AMD3100 and CXCL12, we treated
LgBiT-CXCR4 receptors with VUN400-HiBiT, then allowed
them to reach equilibrium and compete with either CXCL12 or
AMD3100. The addition of these ligands resulted in a decrease
in luminescence over time, signifying reduced complementation
of VUN400-HiBiT with LgBiT-CXCR4 (Figure 6A). Fitting a single
exponential curve to the data revealed apparent koff rates for
VUN400-HiBiT when either AMD3100 (koff 0.039 ± 0.002 min
1;
n = 4) or CXCL12 (koff 0.046 ± 0.001 min
1; n = 5) were simulta-
neously present (p < 0.05 comparing koff values, unpaired t test).
In comparison, the fluorescent ligand CXCL12-AF647 showed
Figure 5. Displacement of VUN400-HiBiT by
Competing Ligands
HEK293 cells stably expressing LgBiT-CXCR4 (A,
C, E) or SNAP-CXCR4 (B, D, F) were treated with
20 nM VUN400-HiBiT and CXCL12, AMD3100, or
IT1t. (B, D, F) 20 nM exogenous LgBiT added to
complement with bound VUN400-HiBiT following
the removal of unbound VUN400-HiBiT with
washing. (A and B) Cells treated with 20 nM
VUN400-HiBiT for 30 min prior to the addition of
CXCL12, AMD3100, or IT1t. (C and D) Cells treated
with VUN400-HiBiT and CXCL12, AMD3100 or IT1t
simultaneously. (E and F) Cells treated with
CXCL12, AMD3100, or IT1t for 2 h prior to the
addition of VUN400-HiBiT. For all experiments, 0%
luminescence was defined as complemented
luminescence obtained with 20 nM VUN400-HiBiT
in the presence of 10 mM AMD3100. Data are
combined mean ± SEM from at least three sepa-
rate experiments, where each experiment was
performed in triplicate. See Table 1 for full details of
number of experimental repeats.
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no statistical difference between the koff values (CXCL12 koff
0.32 ± 0.03 min1; AMD3100 koff 0.42 ± 0.04 min
1; n = 4,
Figure 6B).
DISCUSSION
Nanobodies have been used previously to stabilize GPCRs and
investigate membrane protein conformations to elucidate new
aspects of GPCR function (Zimmermann et al., 2018; Heukers
et al., 2018, 2019; De Groof et al., 2019a). For example, nano-
bodies recognizing active GPCRs have been used to monitor
G-protein-mediated signaling after receptor internalization (Iran-
nejad et al., 2013; Stoeber et al., 2018). The ability to directly
measure nanobody-target engagement is crucial to understand-
ing the nature of this interaction. Split NanoLuciferase
technology (NanoBiT) offered the possibility to use comple-Cell Chemented luminescence to measure small
changes in the interactions between pro-
teins (nanobody-receptor in this case).
This high-throughput, plate-reader-based
approach allowed for the continuous
detection of luminescence to measure
nanobody affinity and kinetic rate con-
stants of nanobody binding to receptors
in a living cell environment.
The expression and ligand binding ca-
pabilities of the LgBiT-tagged CXCR4
were first confirmed in HEK293 cells.
LgBiT-tagged CXCR4 was able to suc-
cessfully complement with exogenously
applied HiBiT-HaloTag to form the full-
length NanoLuc luciferase, and cell sur-
face luminescence was detected using
plate-reader and bioluminescence imag-
ing modalities. Since the size of the
HiBiT-HaloTag fusion protein (34 kDa) pre-vented it fromcrossing the plasmamembrane, the complemented
luminescence was effectively confined to receptors expressed on
the cell surface. The resulting affinity of purified HiBiT for LgBiT-
CXCR4 (pKD 6.43) was significantly lower than those determined
using purified HiBiT and LgBiT fragments (pKD 9.15; Dixon et al.,
2016). We have similarly shown that HiBiT-CXCR4 also has a
much lower affinity for purified LgBiT (pKD 6.64; White et al.,
2020). It is therefore likely that this is a consequence of steric hin-
drance caused by the extracellular components of the receptor to
which theNanoBiT tag is attached. The similarity between the pKD
values obtained here for purified HiBiT-HaloTag interaction with
LgBiT-CXCR4 (6.4) and those obtained with HiBiT-CXCR4 and
purified LgBiT (White et al., 2020) suggest that this is not a conse-
quence of theHaloTag component of the purifiedHiBiT used here.
Consequently, the kinetic values obtained in this study are consid-
ered to be a relatively accurate representation of the binding ki-
netics of the nanobody to CXCR4.mical Biology 27, 1–12, August 20, 2020 7
Table 1. Inhibition of 20 nM VUN400-HiBiT Binding to Whole HEK293 Cells Expressing Either LgBiT-CXCR4 or SNAP-CXCR4
Ligand
LgBiT-CXCR4
n
SNAP-CXCR4
npIC50 (Mean ± SEM) Maximum Inhibition (% 10 mM AMD3100) pIC50 (Mean ± SEM) Maximum Inhibition (% 10 mM AMD3100)
(a) Pre-incubation with VUN400-HiBiT
CXCL12 8.82 ± 0.12 98.2 ± 0.2 5 8.14 ± 0.28a 93.3 ± 8.7 3
AMD3100 7.13 ± 0.18 100 5 6.94 ± 0.16 100 3
IT1t 6.93 ± 0.09 104.4 ± 4.5 5 7.36 ± 0.12 107.1 ± 4.8 3
(b) Simultaneous addition
CXCL12 8.74 ± 0.13 98.8 ± 0.3 6 8.05 ± 0.21a 92.8 ± 6.7 4
AMD3100 6.69 ± 0.19 100 5 7.03 ± 0.24 100 8
IT1t 7.29 ± 0.04 96.5 ± 0.4 3 7.53 ± 0.08 106.8 ± 11.5 3
(c) Pre-incubation with ligands
CXCL12 9.03 ± 0.02 111.5 ± 3.1c 6 8.05 ± 0.41 67.7 ± 11.6c 6
AMD3100 7.93 ± 0.16b 100 6 7.78 ± 0.24b 100 7
IT1t 7.68 ± 0.13b 79.9 ± 3.1c 5 7.52 ± 0.13 102.3 ± 3.6 7
(a) Pre-incubation with VUN400-HiBiT: ligands were added following a 30-min incubation with VUN400-HiBiT. Cells were subsequently incubated for
2 h at 37C and luminescence measured. (b) Simultaneous addition: ligands were added at the same time as VUN400-HiBiT. Cells were subsequently
incubated for 2 h at 37C and luminescencemeasured. (c) Pre-incubation with ligands: ligands were added and the cells were subsequently incubated
for 2 h at 37C prior to addition of 20 nM VUN400-HiBiT. Cells were then incubated for a further 30 min before luminescence was measured. Data are
mean ± SEM from n repeats.
ap < 0.05, unpaired t test comparing pIC50 at SNAP-CXCR4 with that at LgBiT-CXCR4.
bp < 0.05, unpaired t test comparing pIC50 with that obtained when pre-treating tagged CXCR4 with VUN400-HiBiT.
cp < 0.05, unpaired t test comparing maximal inhibition of VUN400-HiBiT binding with 10 mM AMD3100.
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could tolerate the addition of LgBiT via N-terminal fusion without
the loss of binding affinity of the fluorescent ligand CXCL12-
AF647. This tolerance is in agreement with previous studies on
NanoBRET-based ligand binding with CXCR4 receptor tagged
on the N terminus with full-length NanoLuc (White et al., 2020).
Therefore, even though the N terminus of CXCR4 is involved in
the binding of CXCL12 (Crump et al., 1997; Gupta et al., 2001),
our NanoBRET binding data showed that N-terminally fused
LgBiT did not interfere with ligand binding. Similarly, the SNAP
tag on the N terminus of the receptor did not interfere with the
binding of CXCL12 to SNAP-CXCR4. In our studies, the affinity
of CXCL12-AF647 measured using TR-FRET was the same as
that determined at LgBiT-CXCR4.
Single-domain antibodies represent powerful tools for interro-
gating GPCR pharmacology. In most of the studies that em-
ployed nanobodies to elucidate GPCR structural and functional
information, intracellularly binding, non-modified nanobodies
have been used (Rasmussen et al., 2011; Huang et al., 2015;
Che et al., 2018). Here, the CXCR4-targeted nanobody
VUN400 wasmodified on its C-terminal tail to incorporate the Hi-
BiT polypeptide tag. Nanobody binding to LgBiT-CXCR4 was
subsequently detected using complemented luminescence.
The resulting affinity of VUN400-HiBiT at LgBiT-CXCR4 (pKD
7.25) was in very good agreement with previous radioligand
displacement data on HEK293T membrane extracts (pIC50 7.3;
Bobkov et al., 2018) and in reasonable agreement with previous
affinity data of VUN400 on unmodified CXCR4 receptor on
CCRF-CEM cells as determined by flow cytometry (pKD 7.7;
Bobkov et al., 2018). These data are also in agreement with the
general observation that C-terminal fusion to nanobodies does
not affect their binding characteristics (Fang et al., 2016). How-
ever, it should be noted that the binding of VUN400-HiBiT to8 Cell Chemical Biology 27, 1–12, August 20, 2020LgBiT-CXCR4 is likely to involve two binding modes: one
involving the CDR regions of VUN400 to ECL2 of CXCR4, and
the other between the C-terminal HiBiT tag of VUN400 and the
N-terminal LgBiT on the receptor. Kinetic measurements of
nanobody-receptor interactions have traditionally been per-
formed using purified receptors with surface plasmon resonance
assays, often in an environment not indicative of the natural envi-
ronment of the cell. Our approach allowed for the measurement
of kinetic rate constants of nanobody-receptor binding (kon
1.98 3 105 M1 min1, koff 0.032 min
1) in living cells. These ki-
netic rate constants were slower than those of purified HiBiT
binding to LgBiT-CXCR4. Taken together, these data strongly
suggested that the measured affinity and kinetic rate constants
were a result of the more complex binding mode of the nano-
body, first engaging ECL2, followed by the interaction of HiBiT
on the C terminus of the nanobody with the N-terminal LgBiT
on CXCR4.
VUN400-HiBiT could also detect SNAP-tagged CXCR4 recep-
tors without the presence of the LgBiT tag fused to the receptor,
albeit with a reduced apparent affinity. The apparent lower affin-
ity of VUN400-HiBiT for SNAP-CXCR4 is likely to be due to steric
hindrance because of the need for the added purified LgBiT frag-
ment to also access the HiBiT peptide sequence to obtain the
final bioluminescence signal. More interestingly, VUN400-HiBiT
was able to label wild-type CXCR4 receptors expressed under
endogenous promotion in Jurkat cells following addition of exog-
enous purified LgBiT. This makes this technology applicable for
assessing endogenous CXCR4 expression and conformation on
a wide variety of cell lines or tissues.
Interestingly, the addition of saturating concentrations of
chemokine was able to prevent complementation between
VUN400-HiBiT and LgBiT-CXCR4 in transfected HEK cells.
This was also seen in Jurkat cells endogenously expressing
Figure 6. Dissociation Kinetics of Probe-Receptor Complex at
LgBiT-CXCR4
(A) Decrease in VUN400-HiBiT-LgBiT-CXCR4 complemented luminescence
over time following addition of 1 mM CXCL12 or 10 mM AMD3100.
(B) Decrease in specific bioluminescence energy transfer ratio from 10 nM
CXCL12-AF647 following the addition of 1 mM CXCL12 or 10 mM AMD3100.
In these experiments, 20 nM purified HiBiT was added to complement with
LgBiT-CXCR4 prior to the addition of ligands. Data are combinedmean ± SEM
from five (A, CXCL12) or four (A, AMD3100; B) separate experiments, where
each experiment was performed in triplicate.
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tion was reversible, which is consistent with the observed lower
affinity of purified HiBiT for LgBiT-CXCR4. The mechanisms by
which CXCL12 and small molecules, such as AMD3100,
displace VUN400-HiBiT binding ECL2 of CXCR4 are likely to
be allosteric and a consequence of conformational changes
induced in the receptor structure, since the N terminus of
CXCR4 is involved in the binding of CXCL12 (Crump et al.,
1997; Gupta et al., 2001) and small molecules such as
AMD3100 bind to the transmembrane regions of CXCR4 (Rose-
nkilde et al., 2004). Furthermore, there is no overlap between the
binding site of VUN400 in the ECL2 of CXCR4 (Van Hout et al.,
2018) and the binding sites of the small-molecule inhibitors
AMD3100 (Rosenkilde et al., 2004) or IT1t (Wu et al., 2010), which
are within the upper transmembrane region of the receptor. Al-losterism is a consequence of reciprocal interactions between
topically distinct binding sites that reflect the conformational
changes in the CXCR4 structure that they induce. It can be
concluded, therefore, that VUN400-HiBiT is effectively acting
as a conformational sensor.
In all experimental conditions, increasing concentrations of li-
gands resulted in a loss of VUN400-HiBiT binding to LgBiT-
CXCR4 (Figure 5). Adding VUN400-HiBiT before competing
ligands gave IC50 values similar to those determined when
VUN400-HiBiT was added simultaneously to the ligands. How-
ever, when competing ligands were allowed to bind to LgBiT-
CXCR4 before being challenged with VUN400-HiBiT, there was
an apparent increase in the affinities (reduction in IC50 value) of
these ligands (Table 1c). This was particularly marked for
AMD3100, where the potency was an order of magnitude higher
when cells were pre-treated with AMD3100 for 2 h prior to addi-
tion of VUN400-HiBiT. This change in IC50 value is likely to be due
to the nanobody bound to ECL2 sterically interfering with subse-
quent access of the small-molecule inhibitor to its transmem-
brane binding site when both are present together.
Taken together, these data show that the binding of AMD3100
and IT1t to N-terminally tagged CXCR4 receptors can inhibit
VUN400-HiBiT binding to ECL2 of the receptor, probably as a
result of a conformational change. This is consistent with a recip-
rocal negative allosteric interaction between the topically distinct
binding sites for AMD3100 and VUN400-HiBiT, and the known
ability of small-molecule inhibitors such as AMD3100 to induce
conformational rearrangement of the extracellular domains of
CXCR4 (White et al., 2020) and modulate monoclonal antibody
binding (Carnec et al., 2005; Rosenkilde et al., 2004). The confor-
mational changes involving ECL2 induced by both CXCL12 and
AMD3100 in LgBiT-CXCR4 could be followed in real time in living
cells following pre-equilibration with VUN400-HiBiT bound (Fig-
ure 6), and these changes were much slower than the ability of
both ligands to induce dissociation of a fluorescent analog of
CXCL12 from the receptor. It is well known that CXCR4 forms di-
mers or oligomeric complexes (Percherancier et al., 2005; Wang
et al., 2006) and that this organization into higher-order struc-
tures can affect CXCR4 function (Lagane et al., 2008; Ge et al.,
2017). It remains to be established whether the conformational
changes induced by CXCL12 or AMD3100 that are influencing
the binding of VUN400-HiBiT to CXCR4 involve monomeric spe-
cies of CXCR4 or higher-order oligomeric receptor species. This
would, however, require further investigation to determine
whether this was the case.
A striking feature of the effect of CXCL12 on VUN400-HiBiT
binding is the difference in CXCL12 sensitivity between
VUN400-HiBiT binding to LgBiT-CXCR4 and SNAP-CXCR4. In
contrast, the small-molecule inhibitors were equally effective in
inhibiting VUN400-HiBiT binding to LgBiT-CXCR4 and SNAP-
CXCR4. It is possible that this is not a difference in binding of
VUN400-HiBiT to ECL2 but rather a change in the subsequent
interaction between HiBiT on the C terminus of VUN400 (following
its binding to ECL2 of CXCR4) and the LgBiT on the N terminus of
CXCR4. The conformational change induced by the agonist
CXCL12 may affect the relative orientation of the HiBiT on
VUN400-HiBiT (attached to ECL2) toward the LgBiT on the N
terminus of CXCR4 (effectively preventing complementation).
This could allow a more sensitive detection of agonist-inducedCell Chemical Biology 27, 1–12, August 20, 2020 9
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(Figure 5).
In conclusion, the data presented here demonstrate the ability
to detect ligand binding in living cells to CXCR4 using
NanoBiT complementation technology in combination with an
extracellularly binding, ECL2-targeted nanobody. Monitoring
the complemented luminescence enabled the kinetics of the
nanobody-receptor interaction to be followed in real time, as
well as probing for ligand-induced conformational changes in
the extracellular regions of CXCR4. Furthermore, the unique
selectivity of VUN400-HiBiT and the exquisite sensitivity of
NanoLuciferase bioluminescence enabled its use to monitor
ligand binding to and ligand-induced conformational changes
of the endogenous wild-type CXCR4 on the cell surface.
SIGNIFICANCE
The chemokine receptor CXCR4 is a G-protein-coupled re-
ceptor that plays an important role in the immune response
and in the progression of many diseases, including cancer
and HIV infection. Camelid single-domain antibody frag-
ments (nanobodies) offer the specificity of an antibody in a
single 15-kDa immunoglobulin domain. Their small size al-
lows for easy genetic manipulation of the nanobody
sequence to incorporate protein tags, facilitating their use
as biochemical probes. Here, we have used the nanobody
VUN400, which recognizes the second extracellular loop
(ECL2) of the human CXCR4, and NanoBiT luciferase
complementation to measure the direct binding of
VUN400-HiBiT to the second extracellular loop of CXCR4 re-
ceptor, tagged with LgBiT, in living cells and in real time. We
also show that this approach can be used tomonitor confor-
mational changes in the extracellular domains of the recep-
tor induced by agonists and antagonists in living cells. For
example, the clinically used small molecule CXCR4-negative
allostericmodulator AMD3100was able to displace VUN400-
HiBiT binding to ECL2 of CXCR4, despite binding to the
transmembrane regions of the receptor. VUN400-HiBiT
could also detect cell surface expression of recombinant
CXCR4 not containing the LgBiT tag as well as wild-type
receptors endogenously expressed in Jurkat T cells. This
ability to probe for endogenous receptor expression and
ligand-induced conformation changes offers a powerful
tool to investigate G-protein-coupled receptor function in
healthy and diseased cells.
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Data and Code Availability
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Jurkat (male) and HEK293 GloSensor (female) cells were transfected and cultured as described in Method Details.
METHOD DETAILS
Materials
BL21 (DH3) competent cells were obtained from Agilent Technologies (Santa Clara, CA, USA). Isopropyl-b-D-thiogalactopyranoside
and AMD3100 were purchased from Sigma Aldrich. All restriction enzymes, purified LgBiT, purified HiBiT, FuGENE transfection
reagent, and furimazine were purchased from Promega (Wisconsin, USA). Phosphate buffered saline (PBS), Dulbecco’s modified
Eagle’s medium (DMEM), foetal calf serum (FCS), and bovine serum albumin (BSA) were obtained from Sigma Aldrich (UK).
CXCL12 was purchased from PeproTech. IT1t was purchased from Tocris Bioscience. Fluorescent CXCL12-AF647 was obtained
from Almac (Craigavon, UK).e2 Cell Chemical Biology 27, 1–12.e1–e5, August 20, 2020
ll
OPEN ACCESSArticle
Please cite this article in press as: Soave et al., Monitoring Allosteric Interactions with CXCR4 Using NanoBiT Conjugated Nanobodies, Cell Chemical
Biology (2020), https://doi.org/10.1016/j.chembiol.2020.06.006DNA constructs
To create the LgBiT-tagged human CXCR4 receptor construct (LgBiT-CXCR4), the LgBiT sequence was amplified from the pBiT1.1-
N [TK/LgBiT] vector (Promega) and assembled in-frame with the membrane sequence of the 5-HT3A membrane localisation signal
sequence (sig) at the 5’ end of LgBiT using the Gibson assembly PCR technique with the following sets of primers: sigFwd: 5’
CTACTTGGTACCGCCACCATGCGGCTC-3’; sigRev: 5’ CTTCGAGTGTGAAGACCAGAAGCTTCCGGCTGC-3’; LgBiTFwd: 5’
CGGAAGCTTCTGGTCTTCACACTCGAAGATTTC-3’; LgBiTRev: 5’ GATTGGATCCGCTCTGAAAGTACAGATCCTCACCGGAACT
CCCACTGTTG-3’.
The 3’ end of LgBiT was modified to incorporate a short linker (GSSG) and the recognition site for the tobacco etch virus (TEV)
enzyme (residue sequence: EDLYFQS). The resulting nucleotide fragment (sig.LgBiT) contained the sequences for the restriction
enzyme KpnI upstream of the sig sequence and the restriction enzyme BamHI downstream of the linker. This was then ligated to
the pcDNA3.1(+) plasmid containing the human CXCR4 receptor (described in Adlere et al., 2019), creating the fusion of sig.LgBiT,
a Gly-Ser linker and CXCR4 with the methionine start signal removed.
Cell Culture
Jurkat cells (clone E6-1) were maintained in T175 flasks containing RPMI 1640 medium (Lonza) supplemented with 10% fetal calf
serum (FCS; Sigma Aldrich) and 2 mM L-glutamine (Sigma Aldrich) at 37C/5% CO2. Fresh medium was added to the cells every
2-3 days. Cells were passaged at 70% confluency by withdrawing 2.5 ml of the cells into a fresh T175 flask with medium.
HEK293G cells (Glosensor cAMP HEK293, Promega) were grown in T75 flasks containing 25 ml Dulbecco’s Modified Eagle’s Me-
dium (DMEM; Sigma Aldrich, UK) supplemented with 10% FCS at 37C/5% CO2. Cells were passaged at 70-80% confluency using
phosphate buffered saline (PBS; Lonza) and trypsin (0.25% w/v in versene; Lonza). A mixed population HEK293G cell line was
created by transfecting cells with the LgBiT-CXCR4 construct using FuGENE (Promega) according to the manufacturer’s instruc-
tions, followed by selective pressure (1 mg/ml G418) for two to three weeks. HEK293G cells stably expressing the SNAP-CXCR4
construct were kindly gifted from Dr. J. Goulding (University of Nottingham).
Generation and Purification of VUN400-HiBiT Nanobody
The pET28a bacterial expression vector containing the monovalent VUN400 nanobody (Bobkov et al., 2018; Van Hout et al., 2018)
was modified at the C-terminus by fusing the in frame sequence of the HiBiT peptide tag (VSGWRLFKKIS) in between the C-terminal
cMyc and His-tags using PCR cloning, generating the VUN400-HiBiT construct. This was achieved with the following primers:
VUN400HiBiTFwd: 5’ GTGAGCGGCTGGCGGCTGTTCAAGAAGATTAGCGGCCTCGAGCACCACCAC-3’; VUN400-HiBiTRev: 5’-
TGCTGCTGCATTCAGATCCTCTTCTGAGATGAGTTTTTGTTCTG-3. The linear PCR fragment was phosphorylated and subse-
quently ligated to circularise prior to transformation into DH5a Escherichia coli cells to confirm successful cloning.
The pET28a VUN400-HiBiT plasmid was transformed into BL21 (DH3) Escherichia coli cells (Agilent Technologies) for expression
and purification. VUN400-HiBiT was then purified as previously described (de Wit et al., 2017). Briefly, periplasmic expression of
VUN400-HiBiT was induced by 1 mM isopropyl-b-D-thiogalactopyranoside to the bacterial culture media. Periplasmic extracts
were obtained from the freezing and thawing of the cell pellet, and were resuspended in PBS. VUN400-HiBiT was purified from
the periplasmic extract by ion-metal affinity chromatography using Ni-NTA agarose resin (ThermoFischer) according to themanufac-
turer’s instructions. Finally, a buffer exchange to PBS was performed using SnakeSkin (ThermoFischer) dialysis. Nanobody purity
was verified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. Nanobody con-
centration was determined by measuring absorbance at 280 nm using a NanoDrop spectrophotometer (ThermoFisher) and calcu-
lated using the molar extinction coefficient (ε) of this particular nanobody.
NanoBRET Binding Assay
Saturation NanoBRET binding assays were performed on HEK 293 cells stably expressing the LgBiT-CXCR4 receptor. Cells were
plated at 30,000 cells/well in white 96-well plates (Greiner) previously coated with 50 ml poly-D-lysine (mol wt: 70-150 kDa; 10 mg/
ml in PBS) in 100 ml complete media (DMEM with 10% FCS). After 24 hours, the media was removed from each well and replaced
with 100 ml HEPES-buffered saline solution (HBSS; 145 mM NaCl, 5 mM KCl, 1.3 mM CaCl2, 1 mM MgSO4, 10 mM HEPES, 2 mM
sodiumpyruvate, 1.5mMNaHCO3, 10mMD-glucose, pH 7.45) containing 10 nMpurified HiBiT-HaloTag (Promega) and incubated at
37C for 30 minutes. This was sufficient time for HiBiT-LgBiT complementation to occur, forming the fully complemented NanoLuc
enzyme. The HBSSwas then aspirated and the cells washed three times with 100 ml HBSS. Cells were then treated with 100 ml HBSS
containing the relevant concentration of fluorescent ligand in the absence or presence of 10 mM AMD3100 to define non-specific
binding. Cells were incubated for 2 hours at 37C in the dark. The NanoLuc substrate furimazine (Promega) was added to each
well (1:400 final concentration) and allowed to equilibrate for 5 minutes at 37C prior to reading. Luminescence signals were
measured at two wavelengths using a PHERAstar FS plate reader (BMG Labtech, UK) at room temperature. Filtered light was simul-
taneously measured using 460 nm (80-nm bandpass) and >610 nm longpass filters. The resulting BRET ratio was calculated by
dividing the >610 nm emission by the 460 nm emission.
Bioluminescence Imaging
Bioluminescence imaging was performed with an Olympus LV200 Widefield inverted microscope, equipped with a 60x/1.42 NA oil
immersion objective lens. HEK293G cells stably expressing the LgBiT-CXCR4 construct were seeded on a poly-D-lysine coatedCell Chemical Biology 27, 1–12.e1–e5, August 20, 2020 e3
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37C in a humidified 95%air/5%CO2 environment overnight. Prior to imaging, media was removed and replacedwith 2ml HBSS and
the dish was placed on the heated stage of the LV200 for 15 minutes at 37C. For LgBiT-CXCR4 imaging, 200 ml HBSS containing
furimazine (1:400 final concentration) and either 20 nMpurified HiBiT-HaloTag control protein (Promega) or 20 nMVUN400-HiBiT was
added to the dish, and the subsequent luminescence was captured in the open channel with a 45 second (+ 20 nMHiBiT-HaloTag) or
10 second (+ 20 nM VUN400-HiBiT) exposure using a 0.688 MHz EMCCD with a gain of 200.
NanoBiT Nanobody Saturation Binding Assay
Saturation binding with VUN400-HiBiT was performed on HEK 293 cells stably expressing the LgBiT-CXCR4 receptor. Cells were
plated at 30,000 cells/well in white 96-well plates previously coated with poly-D-lysine (10 mg/ml in PBS) in 100 ml complete media
(DMEM with 10% FCS). After 24 hours, the media was removed and replaced with 100 ml HBSS containing VUN400-HiBiT within the
range of 4-500 nM. Where used, CXCL12, AMD3100 or IT1t were also added at this point. The plate was incubated for two hours at
37C. Furimazine (1:400 final concentration) was added to each well and the plate was incubated for a further 15 minutes at 37C.
Luminescence was measured using the PHERAstar FS plate reader.
NanoBiT Nanobody Displacement Binding Assay
Full nanobody displacement assays were performed in HEK293 cells stably expressing either the LgBiT-CXCR4 or SNAP-CXCR4
constructs. Cells (30,000 per well) were plated in white 96-well poly-D-lysine coated plates as described above. After 24 hours,media
was removed and replaced with 100 ml HBSS. Increasing concentrations of displacing ligands were added to the cells. Additionally,
cells were treated with 20 nM VUN400-HiBiT. Depending on the experimental condition, this was as a 30 minute pre-treatment prior
to ligand treatment, simultaneously with competing ligands, or 2 hours following ligand treatment. The cells were incubated at 37C
for 2 and a half hours in total. SNAP-CXCR4 cells were washed 3x with 100 ml warm HBSS to remove unbound VUN400-HiBiT and
then treated with 20 nM exogenous LgBiT to complement with bound VUN400-HiBiT. Furimazine (1:400 final concentration) was
added to each well and the plate was incubated for a further 15 minutes at 37C. Luminescence wasmeasured using the PHERAstar
FS plate reader.
Nanobody displacement assays in T-cells were performed by seeding 100,000 Jurkat cells per well into V-bottom 96-well plates in
100ml warmHBSS. Cells were treatedwith 100 nMVUN400-HiBiT and competing ligands simultaneously and incubated for 2 hours at
37C. The cells were pelleted by centrifugation at 300g for 5 minutes and the supernatant removed and replaced with 200 ml fresh
HBSS. Cells were resuspended via shaking at 1000 r.p.m on an orbital plate shaker for 2 minutes. This wash step was repeated
two more times to remove unbound VUN400-HiBiT. The cells were treated with 20 nM exogenous LgBiT and furimazine (1:400 final
concentration) and transferred to white 96-well plates and luminescence read using a PHERAstar FS plate reader.
NanoBiT Kinetic Measurements
Association kinetic measurements of HiBiT or nanobody binding were performed in HEK293 cells stably expressing LgBiT-CXCR4.
Cells (30,000 per well) were plated in white 96-well poly-D-lysine coated plates (10 mg/ml in PBS) as described above. After 24 hours,
media was removed and replaced with 50 ml HBSS containing furimazine (1:400 final concentration) and incubated at 37C for 10 mi-
nutes and basal luminescence was measured. Increasing concentrations of HiBiT or VUN400-HiBiT were added to the cells in 50 ml
volumes per well. The resulting luminescence was measured over 60 minutes at 37C. Luminescence was measured using the
PHERAstar FS plate reader.
Nanobody and CXCL12-AF647 dissociation kinetic measurements were performed in membranes isolated from HEK293 LgBiT-
CXCR4 cells. Briefly, 10 mg LgBiT-CXCR4 membranes were plated in white 96-well plates containing furimazine (1:400 final concen-
tration) and incubated at 37C for 10 minutes. For experiments with CXCL12-AF647, LgBiT-CXCR4membranes were incubated with
20 nM purified HiBiT during this time to ensure complete complementation. Increasing concentrations of VUN400-HiBiT or CXCL12-
AF647 were added to the wells and luminescence (VUN400-HiBiT) or the BRET ratio (CXCL12-AF647) were measured. A saturating
concentration of competing ligands (CXCL12 or AMD3100) were added following a 30minute (VUN400-HiBiT) or 15minute (CXCL12-
AF647) incubation and the luminescence or BRET ratio was measured for another hour. The BRET ratio was calculated as described
above. Both the BRET ratio and luminescence were measured using the PHERAstar FS plate reader.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data were analysed using Prism 7 software (GraphPad, San Diego, USA).
Saturation NanoBRET curves were fitted simultaneously for total (CXCL12-AF647) and non-specific binding (in the presence of
10mM AMD3100) using the following equation:
Total binding =
Bmax3 ½B
½B+KD +m3B+ c
where Bmax is the maximal specific binding, [B] is the concentration of the fluorescent ligand (nM), KD is the equilibrium dissociation
constant (nM), m is the slope of the non-specific binding component, and c is the y-axis intercept.
Saturation binding curves of VUN400-HiBiT were fitted using the following equation:e4 Cell Chemical Biology 27, 1–12.e1–e5, August 20, 2020
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where Bmax is the maximal specific binding, [B] is the concentration of VUN400-HiBiT, and KD is the equilibrium dissociation con-
stant (nM).
The affinities of ligands at the LgBiT-CXCR4 and SNAP-CXCR4 receptors were calculated from VUN400-HiBiT binding data with a
one-site sigmoidal response curve given by the following equation:
% uninhibited binding= 100 ð1003 ½A
n Þ
½An+ ICn50
+NS
where [A] is the concentration of unlabelled ligand,NS is non-specific binding, n is the Hill coefficient, and IC50 is the concentration of
ligand required to inhibit 50% of VUN400-HiBiT.
Nanobody binding association kinetic data were fitted to the following mono-exponential association function:
Y = Ymax

1 ekobs :t
where Ymax is the specific binding at infinite time, t is the time of incubation, and kobs is the rate constant for the observed rate of
association.
kon and koff values were determined by simultaneously fitting nanobody binding association kinetic curves obtained at different
nanobody concentrations (L) to the equation above with the relationship between kobs and the two kinetic binding rate constants
kon and koff given by:
kon =
kobs  koff
L
Kinetically determined nanobody KD values were determined with the following equation:
KD =
koff
kon
For nanobody dissociation experiments were fitted to the following mono-exponential decay equation:
Y = ðY0  NSÞk:t +NS
where Y0 is the nanobody binding at the time of ligand addition (t0), NS is the nanobody bound at infinite time, and k is the rate con-
stant of nanobody dissociation.
Statistical significance was defined as p<0.05 using an unpaired t-test, or a one-way or two-way ANOVA where appropriate.Cell Chemical Biology 27, 1–12.e1–e5, August 20, 2020 e5
